Decreased Gas6 and sAxl Plasma Levels Are Associated with Hair Loss in COVID-19 Survivors

Post-acute conditions after coronavirus disease 2019 (COVID-19) are quite common, although the underlying pathogenetic mechanisms leading to these conditions are not yet completely understood. In this prospective observational study, we aimed to test the hypothesis that Growth Arrest-Specific 6 (Gas6) and its soluble receptors, Axl (sAxl) and MerTK (sMer), might be implicated. A total of 263 subjects underwent a structured clinical evaluation one year after their hospital discharge for COVID-19, and they consented to donate a blood sample to measure their circulating Gas6, sAxl, and sMer levels. A total of 98 (37.3%) post-COVID-19 subjects complained of at least one residual physical symptom one year after their hospital discharge. Univariate analysis revealed that sAxl was marginally associated with residual symptoms, but at the level of logistic regression analysis, only the diffusing capacity of the lungs for carbon monoxide (DLCO) (OR 0.98, CI 95%: 0.96–0.99; p = 0.007) and the female sex (OR 2.49, CI 95%: 1.45–4.28; p = 0.001) were independently associated with long-lasting symptoms. A total of 69 (26.2%) subjects had hair loss. At the level of univariate analysis, Gas6, sAxl, DLCO, and the female gender were associated with its development. In a logistic regression analysis model, Gas6 (OR 0.96, CI 95%: 0.92–0.99; p = 0.015) and sAxl (OR 0.98, CI 95%; 0.97–1.0; p = 0.014), along with the female sex (OR 6.58, CI 95%: 3.39–12.78; p = 0.0001), were independent predictors of hair loss. Decreased levels of Gas6 and sAxl were associated with a history of hair loss following COVID-19. This was resolved spontaneously in most patients, although 23.7% complained of persistent hair loss one year after hospital discharge.

[1]  G. Cappellano,et al.  Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study , 2022, Frontiers in Immunology.

[2]  D. Sedding,et al.  The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19 , 2022, Cell Reports Medicine.

[3]  D. Lilleri,et al.  Baseline Plasma Gas6 Protein Elevation Predicts Adverse Outcomes in Hospitalized COVID-19 Patients , 2022, Disease markers.

[4]  A. Tosti,et al.  Alopecia in patients with COVID-19: A systematic review and meta-analysis , 2022, JAAD International.

[5]  M. Jafferany,et al.  Association between alopecia areata and COVID-19: A systematic review , 2022, JAAD International.

[6]  G. Biolo,et al.  Are Baseline Levels of Gas6 and Soluble Mer Predictors of Mortality and Organ Damage in Patients with Sepsis? The Need-Speed Trial Database , 2022, Biomedicines.

[7]  Maria Papadopoulou,et al.  Neurological manifestations of long-COVID syndrome: a narrative review , 2022, Therapeutic advances in chronic disease.

[8]  S. Kent,et al.  Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection , 2021, medRxiv.

[9]  E. Wan,et al.  Long-term complications of COVID-19 , 2021, American journal of physiology. Cell physiology.

[10]  G. Cappellano,et al.  Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19 , 2021, Scientific Reports.

[11]  S. Quist,et al.  Keep quiet—how stress regulates hair follicle stem cells , 2021, Signal Transduction and Targeted Therapy.

[12]  S. Villapol,et al.  More than 50 long-term effects of COVID-19: a systematic review and meta-analysis , 2021, Scientific Reports.

[13]  P. Edison,et al.  Long covid—mechanisms, risk factors, and management , 2021, BMJ.

[14]  T. O. Olde Hartman,et al.  Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review , 2021, Family practice.

[15]  Jason D. Buenrostro,et al.  Corticosterone inhibits GAS6 to govern hair follicle stem-cell quiescence , 2021, Nature.

[16]  Rui Yi.  Relax to grow more hair , 2021, Nature.

[17]  G. Nicolaes,et al.  Growth Arrest-Specific Factor 6 (GAS6) Is Increased in COVID-19 Patients and Predicts Clinical Outcome , 2021, Biomedicines.

[18]  D. Brodie,et al.  Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[19]  L. Castello,et al.  Growth Arrest-Specific Gene 6 Administration Ameliorates Sepsis-Induced Organ Damage in Mice and Reduces ROS Formation In Vitro , 2021, Cells.

[20]  L. Bairy,et al.  LONG TERM COMPLICATIONS OF COVID-19 , 2021, International Journal of Medical and Biomedical Studies.

[21]  P. Zeppegno,et al.  Midterm functional sequelae and implications in rehabilitation after COVID19. A cross-sectional study. , 2021, European journal of physical and rehabilitation medicine.

[22]  S. Villapol,et al.  More than 50 long-term effects of COVID-19: a systematic review and meta-analysis , 2021, Scientific Reports.

[23]  P. Sainaghi,et al.  Role of the Gas6/TAM System as a Disease Marker and Potential Drug Target , 2021, Disease markers.

[24]  D. Ozog,et al.  Telogen effluvium associated with COVID‐19 infection , 2021, Dermatologic therapy.

[25]  C. Gramaglia,et al.  Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge , 2021, JAMA network open.

[26]  Guohui Fan,et al.  RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study , 2021, The Lancet.

[27]  Z. Yousaf,et al.  Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection , 2020, IDCases.

[28]  G. Nicolaes,et al.  Role of Vitamin K-Dependent Factors Protein S and GAS6 and TAM Receptors in SARS-CoV-2 Infection and COVID-19-Associated Immunothrombosis , 2020, Cells.

[29]  N. McElvaney,et al.  Characterization of the Inflammatory Response to Severe COVID-19 Illness , 2020, American journal of respiratory and critical care medicine.

[30]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[31]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[32]  C. Pitzalis,et al.  New Insights into the Role of Tyro3, Axl, and Mer Receptors in Rheumatoid Arthritis , 2020, Disease markers.

[33]  Yu‐quan Wei,et al.  AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications , 2019, Molecular Cancer.

[34]  M. Pirisi,et al.  Gas6/TAM System: A Key Modulator of the Interplay between Inflammation and Fibrosis , 2019, International journal of molecular sciences.

[35]  C. Rigamonti,et al.  Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis , 2019, Disease markers.

[36]  P. Cohen,et al.  Gas6/TAM Receptors in Systemic Lupus Erythematosus , 2019, Disease markers.

[37]  J. Di Paola,et al.  GAS6/TAM Pathway Signaling in Hemostasis and Thrombosis , 2018, Front. Med..

[38]  Zhiqiang Ma,et al.  Targeting Gas6/TAM in cancer cells and tumor microenvironment , 2018, Molecular Cancer.

[39]  Zhiqiang Ma,et al.  Molecular insights of Gas6/TAM in cancer development and therapy , 2017, Cell Death & Disease.

[40]  D. Galimberti,et al.  Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[41]  M. Pirisi,et al.  Gas6 as a putative noninvasive biomarker of hepatic fibrosis. , 2016, Biomarkers in medicine.

[42]  E. Rankin,et al.  The Receptor Tyrosine Kinase AXL in Cancer Progression , 2016, Cancers.

[43]  J. Penninger,et al.  The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy , 2016, Cancers.

[44]  A. Lazar,et al.  AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas , 2015, BMC Cancer.

[45]  G. Botti,et al.  AXL is an oncotarget in human colorectal cancer , 2015, Oncotarget.

[46]  G. Lemke.  Biology of the TAM receptors. , 2013, Cold Spring Harbor perspectives in biology.

[47]  M. Pirisi,et al.  Growth Arrest Specific Gene 6 Protein Concentration in Cerebrospinal Fluid Correlates with Relapse Severity in Multiple Sclerosis , 2013, Mediators of inflammation.

[48]  B. Dahlbäck,et al.  Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood , 2010, Journal of thrombosis and haemostasis : JTH.

[49]  B. Dahlbäck,et al.  Gas6 and protein S , 2006, The FEBS journal.

[50]  J. Di Paola,et al.  GAS6/TAM Pathway Signaling in Hemostasis and Thrombosis , 2018, Front. Med..